CSC Financial: GLP-1 Therapeutics Poised for Breakthroughs in NASH and Alzheimer's Disease Indications

36Kr learned that the research report of China Capital Management Co.,Ltd. stated that Novo Nordisk's semaglutide has achieved another success following the previous successful CVOT clinical trial. The Phase III FLOW clinical trial for chronic kidney disease was terminated early as it reached the expected endpoint. The applicable patient population exceeds 100 million globally, with a market potential surpassing $20 billion. GLP-1 class drugs have already demonstrated clinical benefits in Type 2 diabetes, overweight and obesity, cardiovascular and cerebrovascular diseases, heart failure with preserved ejection fraction, and chronic kidney disease, covering a vast population. In the future, GLP-1 class drugs are expected to achieve breakthroughs in indications such as NASH and AD, benefiting more patients while further enhancing the value of the target and the industry.